Skip to main content

Microbix J(MBX-T)
TSX

Today's Change
Real-Time Last Update
Day Low0.2450
Day High0.2500
Open:0.2450
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
Baystreet
Stocks in play: Microbix Biosystems Inc.
ACCESS Newswire
Microbix Engages with Diagnostics Industry Experts
ACCESS Newswire
Microbix Presenting at the 2026 Bloom Burton Conference
Baystreet
Stocks in play: Microbix Biosystems Inc.
ACCESS Newswire
Microbix Exhibiting & Presenting at ESCMID Global 2026
ACCESS Newswire
Microbix Announces Annual Meeting Voting Results
ACCESS Newswire
Microbix Presents Reference-Material Innovations at EUROGIN
Baystreet
Stocks in play: Microbix Biosystems Inc.
ACCESS Newswire
Microbix's Clot-Buster Drug Project Advances
ACCESS Newswire
Microbix Announces Issuance of Stock Options
ACCESS Newswire
Microbix Reports Results for Q1 2026
Baystreet
Stocks in play: Microbix Biosystems Inc.
ACCESS Newswire
Microbix Welcomes The College of American Pathologists as a Client For Supply of QAPs for PT/EQA Programs
Baystreet
Stocks in play: Microbix Biosystems Inc.
ACCESS Newswire
Microbix Schedules Release of Results for Q1 Fiscal 2026
Baystreet
Stocks in play: Microbix Biosystems Inc.
ACCESS Newswire
Microbix Presents Molecular Pathology Platform Results
Newsfile
Upcoming Meeting Dates - January 19, 2026
Baystreet
Stocks in play: Microbix Biosystems Inc.
ACCESS Newswire
Microbix Updates Investor Presentation on its Website
Baystreet
Stocks in play: Microbix Biosystems Inc.
ACCESS Newswire
Microbix Commercializes SARS-CoV-2 (COVID) Recombinant Antigen For Usage in QAPs and Test Manufacturing
GlobeNewswire
Microbix Reports Results for Q4 and Fiscal 2025
GlobeNewswire
Microbix Schedules Release of Results for Q4 Fiscal 2025
Baystreet
Stocks in play: Microbix Biosystems Inc.
GlobeNewswire
Microbix Launches New Products to Support H3N2 Flu Testing
Baystreet
Stocks in play: Microbix Biosystems Inc.
GlobeNewswire
Microbix Announces Initiation of Normal Course Issuer Bid
Baystreet
Stocks in play: Microbix Biosystems Inc.
GlobeNewswire
Microbix & Seegene Mexico Collaborate to Improve Test Accuracy
Baystreet
Stocks in play: Microbix Biosystems Inc.
GlobeNewswire
Microbix Partners with SEKISUI Diagnostics to Support COVID/Flu Tests

Profile

Microbix Biosystems Inc develops biological products and technologies. There are two operating segments: The development, manufacturing, and sale of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows, and viral transport medium to enable collection of patient test samples; and the development and commercialization of novel and proprietary products or technologies such as Kinlytic. Geographically, it derives a majority of revenue from North America and also operates in Europe and other foreign countries.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.